CD8A and neoplasm: Therefore, injectable IL-23 inhibitor drugs, such as guselkumab/Tremfya, risankizumab-rzaa/Skyrizi and tildrakizumab-asmn/Ilumya [355], blocking-up the process of IL-23 (M2 and neutrophils), neutralizing antibodies specific to IL-23p19 (G23-8 antibody can down-modulate MMP9 expression and increased surveillance of CD8+ T cells), and IL-23p19 antagonists can provide effective anti-tumor therapy [126,129,356,357].